A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Ilodecakin (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Nivolumab; Oxaliplatin; Paclitaxel; Pazopanib; Pembrolizumab
  • Indications Breast cancer; Colorectal cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 12 Sep 2017 Updated results (n=34) assessing efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=29) assessing safety and efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in patients with renal cell cancer, presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=21) safety and efficacy in patients with metastatic pancreatic adenocarcinoma, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top